TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
Public ClinicalTrials.gov record NCT00464347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multi-Center, Randomized, Phase II Clinical Trial to Study the Effects of Preservative-Free Triamcinolone Acetonide and Avastin® in Combination With Photodynamic Therapy in Participants With Neovascular Age Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.
Study identification
- NCT ID
- NCT00464347
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Avastin Drug
- Photodynamic Therapy (PDT) Procedure
- Preservative-Free Triamcinolone Acetonide (TAC-PF) Drug
Drug · Procedure
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2007 (Type not available)
- Primary completion
- Not listed
- Completion
- Sep 2007 (Actual)
- Last update posted
- Mar 24, 2010
2007
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retinal Group of Florida | Fort Lauderdale | Florida | 33334 | — |
| Central Florida Retina- Orlando | Orlando | Florida | 32746 | — |
| Retina Specialists | Pensacola | Florida | 32503 | — |
| Elman Retina Group- Baltimore | Baltimore | Maryland | 21237 | — |
| Associated Retinal Consulants | Grand Rapids | Michigan | 49546 | — |
| VitroRetinal Surgery | Minneapolis | Minnesota | 55435 | — |
| Duke University Eye Center | Durham | North Carolina | 27710 | — |
| Palmetto Retina Center | Columbia | South Carolina | 29204 | — |
| Southeastern Retina Associates | Knoxville | Tennessee | 37909 | — |
| Texas Retina Associates-Arlington | Arlington | Texas | 76012 | — |
| Texas Retina Associates-Dallas | Dallas | Texas | 85231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00464347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2010 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00464347 live on ClinicalTrials.gov.